Kyverna Therapeutics (NASDAQ:KYTX) Announces Earnings Results

Key Points

• Kyverna reported quarterly EPS of ($0.80), matching consensus, and the stock rose about 2% to $8.03, valuing the company at roughly $351.7 million.
• Analyst opinions are mixed: MarketBeat shows a Moderate Buy consensus with an average price target of $28.67, while ratings range from a recent sell downgrade to $33 targets from Wells Fargo and Morgan Stanley.
• Kyverna is a clinical-stage biotech developing engineered regulatory T‑cell (Treg) therapies, with an allogeneic Treg candidate in clinical development for ulcerative colitis and additional preclinical programs for rheumatoid arthritis and other inflammatory diseases.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) issued its earnings results on Thursday. The company reported ($0.80) earnings per share for the quarter, hitting the consensus estimate of ($0.80), FiscalAI reports.

Kyverna Therapeutics Stock Up 2.0%

Shares of Kyverna Therapeutics stock traded up $0.16 during trading on Thursday, reaching $8.03. The company's stock had a trading volume of 559,340 shares, compared to its average volume of 748,013. Kyverna Therapeutics has a 1-year low of $1.78 and a 1-year high of $13.67. The company has a 50-day simple moving average of $8.31 and a two-hundred day simple moving average of $7.55. The company has a market cap of $351.71 million, a price-to-earnings ratio of -2.15 and a beta of 3.32.

Institutional Investors Weigh In On Kyverna Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE boosted its holdings in Kyverna Therapeutics by 41.6% in the fourth quarter. Bank of America Corp DE now owns 21,788 shares of the company's stock worth $81,000 after acquiring an additional 6,400 shares in the last quarter. Cubist Systematic Strategies LLC increased its holdings in shares of Kyverna Therapeutics by 31.1% during the first quarter. Cubist Systematic Strategies LLC now owns 68,628 shares of the company's stock valued at $132,000 after acquiring an additional 16,267 shares in the last quarter. AQR Capital Management LLC purchased a new position in shares of Kyverna Therapeutics in the 1st quarter valued at approximately $137,000. Rhumbline Advisers boosted its stake in Kyverna Therapeutics by 22.0% in the 1st quarter. Rhumbline Advisers now owns 31,614 shares of the company's stock worth $61,000 after purchasing an additional 5,694 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in Kyverna Therapeutics in the 2nd quarter worth approximately $107,000. 18.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

KYTX has been the topic of several research reports. Wall Street Zen lowered Kyverna Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, March 21st. Wells Fargo & Company upped their price objective on shares of Kyverna Therapeutics from $31.00 to $33.00 and gave the stock an "overweight" rating in a research note on Tuesday, December 16th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Kyverna Therapeutics in a report on Monday, December 29th. Finally, Morgan Stanley set a $33.00 target price on shares of Kyverna Therapeutics in a research report on Monday, December 15th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Kyverna Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $28.67.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company's lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.